Papillary Renal Cell Carcinoma: Risks, Treatments, and More

What Is Papillary Renal Cell Carcinoma?

Papillary renal cell carcinoma, commonly shortened to papillary RCC or pRCC, is a cancer that develops in the lining of the kidney’s tiny filtering tubes. It belongs to the broader renal cell carcinoma family, which accounts for most kidney cancers in adults.

Papillary RCC is generally considered the second most common renal cell carcinoma subtype after clear-cell RCC. It represents roughly 15% of renal cell carcinomas, although estimates vary among patient populations and pathology studies.

The word papillary describes the finger-like or branching structures that the tumor cells form under a microscope. It does not mean that every papillary tumor behaves in exactly the same way. In fact, tumors placed under the papillary umbrella can differ significantly in their genes, grade, growth rate, and response to treatment.

A note about type 1 and type 2 papillary RCC

Older pathology reports often divide papillary RCC into type 1 and type 2. Type 1 generally referred to tumors with smaller cells arranged in a single layer, while type 2 described a more varied group of tumors with larger cells and different microscopic features.

Modern kidney tumor classification has moved beyond this simple split. Current pathology standards no longer recommend treating type 1 and type 2 as the complete classification system because the old type 2 category included several biologically distinct cancers. Some tumors previously labeled type 2 may now receive a more precise diagnosis based on their molecular features, such as fumarate hydratase-deficient renal cell carcinoma.

That is why an expert pathology review can matter, particularly when a tumor is aggressive, unusual, diagnosed at a young age, or associated with a strong family history.

What Causes Papillary Renal Cell Carcinoma?

Most cases are sporadic, meaning they arise without a clearly inherited cause. Cancer begins when genetic changes allow kidney cells to grow, divide, and survive when they normally would not. Researchers understand several pathways involved in papillary RCC, but they usually cannot point to one specific event and say, “That is exactly what caused this person’s cancer.” Biology is rarely that polite.

Some papillary tumors involve abnormal activity in the MET signaling pathway, which helps regulate cell growth. Other tumors contain changes affecting entirely different biological systems. Molecular testing may therefore be useful in selected advanced cancers, especially when the results could help identify a targeted therapy or clinical trial.

Papillary Renal Cell Carcinoma Risk Factors

Having a risk factor does not mean that someone will develop kidney cancer, and people with no obvious risk factors may still receive a diagnosis. However, several factors have been associated with a higher overall risk of renal cell carcinoma.

Smoking

Cigarette smoking increases the risk of renal cell carcinoma. The risk tends to rise with the amount and duration of tobacco exposure, although it gradually decreases after a person quits. Stopping smoking remains worthwhile at any age and can improve heart, lung, blood vessel, and surgical health as well.

Excess body weight

Overweight and obesity are associated with an increased risk of kidney cancer. Possible explanations include changes in hormones, inflammation, insulin signaling, and blood pressure. Weight is only one part of a person’s health, however, and a cancer diagnosis should never be reduced to a blame game involving the bathroom scale.

High blood pressure

Hypertension has been linked with renal cell carcinoma. Researchers continue to study how much of this association comes from high blood pressure itself and how much may involve related health conditions or medications. Regardless, keeping blood pressure controlled protects the kidneys, heart, brain, and blood vessels.

Chronic kidney disease and long-term dialysis

People with advanced kidney disease, particularly those who have received dialysis for many years and developed acquired cystic kidney disease, have an elevated risk of kidney tumors. Regular kidney care and appropriate imaging are especially important in this population.

Age, sex, and occupational exposure

Kidney cancer is diagnosed more often in older adults and in men. Workplace exposure to substances such as trichloroethylene, an industrial solvent, has also been associated with renal cell carcinoma. Employers and workers should follow established chemical-handling and protective-equipment standards.

Inherited genetic syndromes

A small but important portion of papillary kidney cancers is hereditary. Hereditary papillary renal carcinoma is linked to inherited pathogenic variants in the MET gene. Affected people may develop multiple tumors, tumors in both kidneys, or kidney cancer at a younger-than-expected age.

Another condition, hereditary leiomyomatosis and renal cell cancer, is associated with pathogenic variants in the FH gene. The related kidney cancer can be aggressive and requires specialized surveillance and treatment. People with this syndrome may also develop skin growths or uterine fibroids at relatively young ages.

Genetic counseling may be recommended when kidney cancer occurs early in life, affects both kidneys, produces multiple tumors, appears in several relatives, or has unusual pathological features. Counseling is useful before testing because genetic results can affect both the patient and biological family members.

Possible Symptoms of Papillary Kidney Cancer

Small kidney tumors frequently cause no symptoms. Many are found incidentally during an ultrasound, CT scan, or MRI ordered for an unrelated complaint. In other words, a scan looking for one problem occasionally discovers an uninvited kidney guest.

When symptoms occur, they may include:

• Blood in the urine, which may look pink, red, or tea-colored
• Persistent pain in the side, back, or area below the ribs
• A lump or fullness in the abdomen or flank
• Unexplained weight loss or reduced appetite
• Fatigue, weakness, or anemia
• Recurrent fever without a clear infection
• Swelling in the legs or ankles

These symptoms can also result from kidney stones, infections, benign cysts, and many other conditions. Visible blood in the urine should nevertheless be evaluated promptly, even when it appears once and then disappears.

How Papillary Renal Cell Carcinoma Is Diagnosed

Medical history and laboratory testing

The evaluation usually begins with a medical history, physical examination, urine testing, a complete blood count, and blood chemistry tests. Kidney function is commonly measured with creatinine and an estimated glomerular filtration rate. Liver tests, calcium levels, and other laboratory values may help assess general health or possible effects of advanced disease.

Imaging

Contrast-enhanced CT is commonly used to examine a kidney mass, determine its size, and see whether it involves nearby blood vessels, lymph nodes, or organs. MRI may be preferred when more detail is needed, when a tumor extends toward major veins, or when CT contrast is unsuitable. Ultrasound can distinguish some cystic and solid masses but may not provide enough information for complete staging.

Biopsy and pathology

A renal mass biopsy uses a needle to remove small tissue samples for laboratory examination. Not every kidney mass must be biopsied before surgery, but biopsy can be especially helpful when imaging is uncertain, active surveillance is being considered, systemic therapy will begin before surgery, or the result could change treatment.

A pathologist identifies the tumor subtype, grade, and other microscopic features. For a complicated or unusual case, review by a pathologist who specializes in genitourinary cancer can help confirm that the tumor is truly papillary RCC rather than another kidney cancer that merely resembles it.

Stage and grade

Stage describes how far the cancer has spread. Localized disease remains in the kidney, regional disease has reached nearby structures or lymph nodes, and metastatic disease has spread to distant areas such as the lungs, bones, liver, brain, or distant lymph nodes.

Grade describes how abnormal the tumor cells appear and provides clues about likely behavior. Stage, grade, tumor size, molecular features, kidney function, overall health, and personal priorities all influence the treatment plan.

Treatment for Localized Papillary Renal Cell Carcinoma

Partial nephrectomy

For many small, localized tumors, partial nephrectomy is preferred when technically possible. The surgeon removes the tumor and a rim of surrounding tissue while preserving the remainder of the kidney. This kidney-sparing approach can reduce the risk of future chronic kidney disease, especially in people who already have reduced kidney function, tumors in both kidneys, or a hereditary cancer syndrome.

Radical nephrectomy

A radical nephrectomy removes the entire affected kidney and sometimes nearby tissue or lymph nodes. It may be necessary when the tumor is large, centrally located, invading nearby structures, or impossible to remove safely while leaving a useful portion of the kidney.

Many people live well with one healthy kidney. Follow-up still includes monitoring blood pressure, kidney function, medication use, and conditions such as diabetes that can place extra strain on the remaining kidney.

Active surveillance

Selected small kidney masses may be monitored with scheduled imaging rather than treated immediately. Active surveillance is most often considered for older adults, people with serious medical conditions, or patients whose tumors appear unlikely to cause harm in the near future.

This is not the same as ignoring the tumor. It is a structured plan with repeat scans and clear triggers for intervention if the mass grows or changes.

Thermal ablation

Cryoablation freezes tumor tissue, while radiofrequency or microwave ablation destroys it with heat. These procedures may be options for small tumors in people who are not ideal surgical candidates. Local recurrence can be more likely after ablation than after surgical removal, so careful follow-up is essential.

Treatment for Advanced or Metastatic Papillary RCC

Advanced papillary RCC deserves a treatment plan designed specifically for non-clear-cell kidney cancer. Many landmark kidney cancer trials enrolled mostly or exclusively patients with clear-cell RCC, so an experienced medical oncologist should consider evidence that directly includes papillary tumors.

Cabozantinib and other targeted therapies

Cabozantinib is a tyrosine kinase inhibitor that blocks several proteins involved in tumor growth and blood-vessel formation, including MET, VEGF receptors, and AXL. In the randomized PAPMET trial, cabozantinib delayed cancer progression longer than sunitinib in patients with advanced papillary RCC. It has consequently become an important treatment option for this disease.

Other targeted drugs, including sunitinib, lenvatinib, and everolimus, may be considered in certain situations. A highly selective MET inhibitor may be relevant when testing confirms a MET-driven tumor, although access may depend on clinical-trial eligibility and the precise molecular finding.

Immunotherapy

Checkpoint inhibitors help immune cells recognize and attack cancer. Pembrolizumab has demonstrated activity as a single agent in previously untreated non-clear-cell RCC, including papillary tumors.

Combinations such as nivolumab plus cabozantinib have also produced encouraging responses in clinical studies of non-clear-cell RCC. Nivolumab plus ipilimumab or pembrolizumab-based combinations may be discussed for selected patients. The best option depends on tumor characteristics, previous treatment, autoimmune conditions, organ function, expected side effects, and whether a regimen is specifically approved or being used based on broader RCC evidence.

Radiation therapy

Traditional radiation is not usually the main treatment for a removable kidney tumor. It can nevertheless relieve pain, bleeding, or neurological symptoms caused by metastases. Highly focused stereotactic radiation may also control selected tumors in the brain, bone, lung, or other locations.

Chemotherapy

Standard cytotoxic chemotherapy usually has limited effectiveness against papillary RCC and is not a routine first choice. Chemotherapy may be used for certain rare kidney cancer subtypes, which is another reason an exact pathology diagnosis matters.

Clinical trials

Because papillary RCC is less common than clear-cell RCC, clinical trials play an especially important role. Studies are evaluating new immunotherapy combinations, MET-directed drugs, personalized treatments, and strategies based on tumor genetics. Asking about a trial does not mean standard treatment has failed; it may provide access to a promising option at any appropriate point in care.

Side Effects and Supportive Care

Targeted drugs can cause diarrhea, fatigue, high blood pressure, mouth soreness, appetite changes, skin problems, and hand-foot syndrome. Immunotherapy can overstimulate the immune system and inflame organs such as the thyroid, intestines, liver, lungs, skin, or adrenal glands.

Patients should report new symptoms early rather than saving them for the next appointment. A minor symptom on Tuesday can become a major nuisance by Friday, and oncology teams generally prefer an early phone call to an avoidable hospital visit.

Supportive care may include nutrition counseling, pain management, physical therapy, blood pressure treatment, mental health services, fertility counseling, and help with fatigue or sleep. Palliative care can be used alongside cancer treatment at any stage to improve comfort and quality of life; it is not limited to end-of-life care.

Prognosis and Follow-Up

The outlook for papillary RCC depends primarily on stage, grade, tumor biology, and response to treatment. Localized kidney cancer can often be cured with surgery. Advanced disease is more difficult to cure, but modern targeted therapies and immunotherapies can shrink or stabilize tumors for meaningful periods.

Broad kidney cancer survival statistics cannot predict exactly what will happen to one person. They combine patients with different tumor subtypes, treatments, ages, and health conditions, and they necessarily reflect people diagnosed several years earlier.

After treatment for localized disease, follow-up usually includes physical examinations, blood tests, kidney function monitoring, and periodic imaging of the abdomen and chest. The schedule is adjusted to the original tumor’s size, stage, grade, surgical findings, and estimated recurrence risk.

Can Papillary RCC Be Prevented?

No strategy can prevent every case, particularly cancers caused by inherited gene variants. However, avoiding tobacco, maintaining a sustainable healthy weight, controlling blood pressure, using workplace protection around hazardous chemicals, and managing chronic kidney disease may reduce overall kidney cancer risk or protect long-term kidney health.

People with a known hereditary syndrome need a specialist-designed surveillance program. Routine screening of the entire population for kidney cancer is not generally recommended, but high-risk families may benefit from scheduled imaging beginning at an age determined by the specific syndrome.

Experiences People May Have During Papillary RCC Care

The following examples are composites based on common care experiences rather than stories about identifiable patients.

The accidental diagnosis

One common experience begins with a scan ordered for something completely different. A person visits the emergency department for abdominal pain, expecting to hear about a kidney stone or gallbladder problem, and instead learns that a mass was found on the kidney.

The first few days can feel surreal. The patient may hear “small renal mass,” “enhancement,” “possible RCC,” and “urology referral” before anyone can confirm exactly what the mass is. Internet searches then produce everything from reassuring surgical outcomes to frightening metastatic-cancer stories, often within the same five minutes.

A helpful next step is to slow the process down enough to gather the right information: How large is the mass? Is it confined to the kidney? Is partial nephrectomy possible? Is a biopsy needed? Should the images or eventual pathology be reviewed at a center experienced with non-clear-cell kidney cancers?

Recovering after kidney surgery

After partial or radical nephrectomy, patients commonly describe soreness, fatigue, appetite changes, and frustration that recovery is not perfectly linear. A person may feel surprisingly energetic one morning, complete several household tasks, and then discover that the body has scheduled an unsanctioned three-hour nap.

Walking usually becomes an important part of recovery, but lifting restrictions and wound-care instructions must be followed. Many patients also become intensely interested in every laboratory result involving creatinine. That attention is understandable, although one isolated number rarely tells the entire kidney-function story.

Questions about food are common. Most patients do not need an extreme “kidney cleanse,” suspicious detox tea, or a diet consisting exclusively of foods discovered by an adventurous wellness influencer. The sensible plan is individualized: stay hydrated as directed, limit excessive sodium, eat a balanced diet, manage blood pressure and diabetes, and ask the medical team before using supplements or frequent anti-inflammatory pain medicines.

Starting systemic treatment

For metastatic papillary RCC, the transition to targeted therapy or immunotherapy can create a different rhythm. Appointments, blood tests, medication deliveries, blood pressure readings, and scan dates begin to organize the calendar.

A patient taking cabozantinib may need help managing diarrhea, mouth sensitivity, fatigue, appetite loss, skin changes, or tenderness on the hands and feet. Dose reductions sometimes feel like a setback, but they are a normal tool for balancing cancer control with daily function. The strongest dose is not automatically the best dose if side effects make continued treatment impossible.

Someone receiving immunotherapy may feel well for weeks and then notice a persistent cough, rash, diarrhea, unusual weakness, or headache. Reporting these changes quickly matters because immune-related inflammation is often easier to treat when recognized early.

Living from scan to scan

Many patients use the word “scanxiety” to describe the tension before imaging and results. The mind may rehearse every possible outcome while the rest of the world behaves rudely normallyemails arrive, laundry accumulates, and somebody still wants to discuss the Wi-Fi password.

Practical coping strategies include scheduling the results appointment soon after the scan, bringing a support person, writing questions in advance, and asking for plain-language explanations. Some people want to know every measurement. Others prefer the headline first: stable, smaller, larger, or new.

Finding the right expertise

Because papillary RCC is less common, patients often benefit from at least one consultation with a kidney cancer specialist. A second opinion may confirm the original plan rather than replace it, which can still provide valuable peace of mind.

The most productive care relationships allow room for both medical evidence and personal priorities. One patient may value an aggressive treatment strategy despite substantial side effects. Another may prioritize work, caregiving, travel, or symptom control. Shared decision-making means discussing those goals honestly rather than pretending everyone has the same definition of a good treatment outcome.

Above all, living with papillary RCC is not one continuous dramatic battle scene. It includes ordinary meals, small victories, irritating insurance calls, recovery milestones, jokes in waiting rooms, and days when cancer receives less attention than a broken appliance. The diagnosis may alter a life, but it does not erase the rest of it.

Questions to Ask the Cancer Care Team

• Has the pathology been reviewed by a kidney cancer specialist?
• What are the tumor’s exact subtype, stage, grade, and molecular features?
• Could this cancer be related to an inherited syndrome?
• Can the tumor be treated with partial nephrectomy?
• What are the benefits and risks of surveillance, ablation, or surgery?
• For advanced disease, which evidence specifically applies to papillary RCC?
• Would tumor sequencing or a clinical trial affect my options?
• Which side effects require an immediate phone call?
• How will treatment and surgery affect long-term kidney function?

Conclusion

Papillary renal cell carcinoma is not simply a smaller footnote in the kidney cancer handbook. It is a biologically varied disease that requires accurate pathology, careful staging, and treatment decisions based on evidence for non-clear-cell RCC.

Localized tumors are often managed successfully with kidney-sparing surgery or radical nephrectomy. For advanced disease, cabozantinib, immunotherapy, combination regimens, molecular testing, and clinical trials have expanded the available options. Genetic counseling is particularly important for younger patients, people with bilateral or multiple tumors, and families with repeated kidney cancer diagnoses.

Anyone facing papillary RCC should seek an individualized plan from qualified specialists. Online information can make the vocabulary less intimidating, but it cannot replace pathology review, medical evaluation, or a treatment recommendation based on the complete clinical picture.